Clinical Scientist Consultant Jobs

Experience in immune-oncology clinical trials? Looking for a consulting early development clinical scientist position? This is an opportunity to get involved at the ground floor of an emerging scientific field by joining the Industry Leader in Glyco-Immunology. We are seeking a clinical scientist consultant with clinical trial experience who is comfortable treading new ground.

Job Summary:

Palleon Pharmaceuticals is seeking a clinical scientist consultant who has oncology clinical trial experience. Reporting to the VP – Clinical Development, the candidate will be expected to contribute to several oncology clinical trials in Palleon’s growing portfolio.

Position Responsibilities:

• Assess trends in safety data, review serious adverse event cases and safety narratives in collaboration with the team.
• Contribute to and review the content of clinical and regulatory documents, including but not limited to clinical study protocols, training materials, investigator brochures, annual reports, informed consents, clinical study reports/narratives and study plans.
• Perform literature searches, coordinate scientific discussions relevant to designing study protocols and advancing programs into the clinic.
• Support clinical development team in advancing our first-in-class glyco-immunology drug development platform.
• Perform ongoing clinical data review and critical analysis of study data, partnering with clinical development and data management.

Qualifications:

· Experienced clinical scientist with proven track record in solid tumor early clinical development.

• Experience in oncology drug development and/or immune-oncology clinical trials required.
• Strong knowledge of FDA/global regulatory requirements, ICH regulations, and GCP.
• Proven scientific writing skills for clinical/regulatory documents, and ability to evaluate, interpret and summarize complex data.
• Excellent communication and interpersonal skills.

Who We Are:

Palleon Pharmaceuticals, co-founded by Nobel laureate Carolyn Bertozzi, is a biotechnology company pioneering glyco-immunology drug development to transform the treatment of cancer and inflammatory diseases. The Company’s proprietary platforms overcome technical barriers unique to glycobiology to enable drug discovery, patient selection, and indication prioritization to de-risk clinical development. The company’s lead program in oncology, E-602, is a first-in-class, glyco-immune checkpoint inhibitor which restores antitumor immunity by enzymatically degrading immunosuppressive sialoglycans on hypersialylated tumors and immune cells. It is being evaluated in a Phase 1/2 clinical trial. Palleon has a rich pipeline of additional drug candidates including several advancing toward IND-enabling studies.